Loading…
BioNTech SE is projected to rise to $115.48 by 2027, a +26% move from its current price of $91.49. BNTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $89.98 | $91.50 | $93.05 | +0.02% |
| Jul 14 | $89.37 | $91.52 | $93.71 | +0.03% |
| Jul 15 | $88.91 | $91.53 | $94.23 | +0.05% |
| Jul 16 | $88.53 | $91.55 | $94.67 | +0.06% |
| Jul 17 | $88.19 | $91.56 | $95.06 | +0.08% |
| Jul 18 | $87.89 | $91.58 | $95.41 | +0.09% |
| Jul 19 | $87.62 | $91.59 | $95.74 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $87.62 | $91.59 | $95.74 | +0.11% |
| Week 2 | $86.12 | $91.69 | $97.62 | +0.22% |
| Week 3 | $85.00 | $91.79 | $99.12 | +0.33% |
| Week 4 | $84.09 | $91.89 | $100.41 | +0.44% |
| Week 5 | $83.31 | $91.99 | $101.58 | +0.55% |
| Week 6 | $82.61 | $92.09 | $102.66 | +0.66% |
| Week 7 | $81.99 | $92.19 | $103.67 | +0.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide, as well as drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, and Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, it progresses oncology drugs under Phase II clinical trial comprising BNT116 for advanced non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advanced colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox.
The company was incorporated in 2008 and is headquartered in Mainz, Germany.
BioNTech SE (BNTX) is a healthcare company focused on immunotherapies and oncology drugs, with a current price of $92.22 and a market cap of $23.32B. It is ranked 540 by market capitalization among listed stocks.
The year-by-year forecast outlines a path from a 2026 average price of $92.22 toward substantially higher levels by 2050, with a 2026 max of $118.42 and a 2050 max of $1,025.79. The outlook shows bullish momentum beginning in 2027, culminating in a 2050 average price of $627.12 and a maximum of $1,025.79, implying a long-run upside albeit with inherent uncertainty.
A major floor 13.1% below — a decisive break under it would weaken the trend.
The nearest floor, 6.5% below — buyers have tended to step in here.
The nearest ceiling, 6.6% above — a clean break opens room to run.
A major ceiling 22.0% above — clearing it would confirm fresh momentum.
Key BNTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BNTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $93.24 | Sell | $92.94 | Sell |
| MA 10 | $93.62 | Sell | $92.96 | Sell |
| MA 20 | $92.04 | Sell | $92.40 | Sell |
| MA 50 | $92.22 | Sell | $92.91 | Sell |
| MA 100 | $95.16 | Sell | $95.01 | Sell |
| MA 200 | $99.00 | Sell | $97.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.85 | Neutral |
| Stoch RSI (14) | 3.28 | Buy |
| CCI (20) | -20.93 | Neutral |
| Williams %R (14) | -80.25 | Info |
| MACD (12,26,9) | 0.15 | Buy |
| ROC (12) | 0.96 | Buy |
| Bollinger %B (20,2) | 0.43 | Neutral |
| Stochastic %K (14) | 19.75 | Buy |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | 1.96 | Buy |
| Ultimate (7,14,28) | 45.76 | Neutral |
| Momentum (10) | 1.49 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 92.57 | Sell |
| ADX (14) | 10.58 | Neutral |
| ATR (14) | 1.45 | Info |
The near-term technical outlook is NEUTRAL. The RSI(14) sits at 50, indicating a balanced momentum around mid-range.
The stock’s short-term moving averages show the 50-day SMA at $94.85 and the 200-day SMA at $99.61, suggesting price alignment between recent and medium-term trends. Support is listed at $85.50, with resistance at $95.95, framing a potential trading band in the coming weeks.
The 30-day price range spans from a low of $81.76 to a high of $104.01, illustrating a defined but evolving trading corridor over the last month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $83.89 | $91.49 | $117.76 | 0% | Neutral | |
| $94.57 | $115.48 | $147.42 | +26% | Bullish | |
| $109.67 | $136.43 | $178.88 | +49% | Bullish | |
| $117.22 | $148.06 | $198.26 | +62% | Bullish | |
| $117.45 | $150.36 | $204.97 | +64% | Bullish | |
| $129.26 | $167.50 | $231.94 | +83% | Bullish | |
| $139.30 | $182.55 | $256.38 | +100% | Bullish | |
| $153.19 | $202.87 | $288.60 | +122% | Bullish | |
| $181.19 | $242.34 | $348.87 | +165% | Bullish | |
| $188.33 | $254.27 | $370.11 | +178% | Bullish | |
| $277.44 | $390.68 | $595.95 | +327% | Bullish | |
| $429.74 | $649.01 | $1,061.20 | +609% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $83.89 | $91.49 | $110.82 | +0.00% |
| August 2026 | $80.61 | $94.38 | $112.89 | +3.15% |
| September 2026 | $78.89 | $92.80 | $111.86 | -1.67% |
| October 2026 | $79.54 | $93.94 | $113.99 | +1.23% |
| November 2026 | $81.29 | $96.34 | $117.54 | +2.56% |
| December 2026 | $80.77 | $96.03 | $117.76 | -0.32% |
Click any year to see its month-by-month BNTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
BioNTech SE's 2026 outlook centres on $91.49, within a $83.89 to $117.76 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, BNTX could reach as high as $147.42, with a base case around $115.48 and support toward $94.57 — roughly +26% from $91.49. Momentum favours further upside here.
Expect BNTX to range from $109.67 to $178.88 through 2028. The $136.43 average target implies a +49% move from current prices. That is up +18% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The BNTX price prediction for 2029 points to an average of $148.06 (low $117.22, high $198.26) — a potential gain of +62% on today's $91.49. Momentum favours further upside here.
In 2030, BNTX is projected to trade between $117.45 and $204.97, averaging $150.36 — a potential gain of +64% from today's $91.49. That is up +2% on the projected 2029 average. Buyers look set to stay in control over this stretch.
BioNTech SE's 2031 outlook centres on $167.50, within a $129.26 to $231.94 range. That is up +11% on the projected 2030 average. That marks a +83% change versus current levels. Momentum favours further upside here.
By 2032, BNTX could reach as high as $256.38, with a base case around $182.55 and support toward $139.30 — roughly +100% from $91.49. Buyers look set to stay in control over this stretch.
Expect BNTX to range from $153.19 to $288.60 through 2033. The $202.87 average target implies a +122% move from current prices. That is up +11% on the projected 2032 average. Momentum favours further upside here.
The BNTX price prediction for 2034 points to an average of $242.34 (low $181.19, high $348.87) — a potential gain of +165% on today's $91.49. Buyers look set to stay in control over this stretch.
In 2035, BNTX is projected to trade between $188.33 and $370.11, averaging $254.27 — a potential gain of +178% from today's $91.49. That is up +5% on the projected 2034 average. Momentum favours further upside here.
BioNTech SE's 2040 outlook centres on $390.68, within a $277.44 to $595.95 range. That is up +54% on the projected 2035 average. That marks a +327% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, BNTX could reach as high as $1,061.20, with a base case around $649.01 and support toward $429.74 — roughly +609% from $91.49. Momentum favours further upside here.
Investing $1,000 in BNTX today (≈ 10.930156 BNTX) could be worth
$7,093.81
+$6,093.81 (+609%) by 2050 · US Dollar
Based on the average projected BNTX price of $649.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BNTXwould be worth at today's price.
$1,000 invested in BNTX on Jul 10, 2025 (≈ 8.77809 BNTX) would be worth
$803.11
-$196.89 (-19.7%) today · 0.80× · US Dollar
Based on a BNTX entry price of $113.92 vs. today's $91.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $97.54 | $937.93 | -6.2% |
| 1 month ago | $86.15 | $1,061.98 | +6.2% |
| 3 months ago | $95.5 | $958.01 | -4.2% |
| 6 months ago | $102.18 | $895.38 | -10.5% |
| 1 year ago | $113.92 | $803.11 | -19.7% |
| All time (5.0y) ago | $207.84 | $440.19 | -56.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BNTX forecast.
Our base-case forecast reaches $180.00 around 2032.
Implied market cap at $180.00: $45.52B
The multi-year forecast paints a steadily rising price path, with the average price climbing from $92.22 in 2026 to $627.12 in 2050 and a potential high of $1,025.79 in 2050. The 2027 average is $119.59, followed by continual gains through 2040 ($378.56) and beyond into 2050 ($627.12).
Projected returns (ROI) move from 0% in 2026 to 29.7% in 2027, 46.9% in 2028, 57.9% in 2029, 66.3% in 2030, and accelerating to 310.5% by 2040 and 580% by 2050. Sentiment shifts to BULLISH from 2027 onward, reflecting a strong longer-term bullish outlook.
These figures illustrate a long-run upside potential while underscoring that forecasts are estimates, not guarantees, and are subject to market and business risks.
Tap a question to reveal the answer.
Avg $153.41; min $119.73; max $209.34; ROI 66.3%; sentiment BULLISH.
The forecast shows bullish momentum from 2027 onward, with the avg price rising to $627.12 by 2050 and ROI reaching 580%. These are estimates, not guarantees.
Yes. The 2026 max is $118.42, and subsequent years show higher averages, with a 2050 max of $1,025.79.
$81.76 to $104.01.
Avg $378.56; min $268.70; max $577.76; ROI 310.5%; sentiment BULLISH.
BioNTech SE Community Discussion
0Share your BioNTech SE price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.